SCHEMBL14303

SCHEMBL14303

O=C(NC1CCNCC1)c1ccc(-c2cc3cn(-c4ccc(CNCCCCl)cc4)c(=O)nc3[nH]2)cc1F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
PARP1 P09874 2/20 0.37
TNK2 Q07912 1/20 0.37
TNK1 Q13470 1/20 0.37
MET P08581 2/20 0.36
AKT1 P31749 1/20 0.36
JAK2 O60674 2/20 0.36
BRD4 O60885 2/20 0.36
PTK2 Q05397 2/20 0.35
JAK1 P23458 1/20 0.35
BRD2 P25440 1/20 0.35
JAK3 P52333 1/20 0.35
BRD3 Q15059 1/20 0.35
BRDT Q58F21 1/20 0.35
TTK P33981 4/20 0.35
DHODH Q02127 1/20 0.35
CCNT1 O60563 1/20 0.34
CCNA2 P20248 1/20 0.34
CDK2 P24941 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13856 0.86 KLKB1 (0.38) PTK2CNR1IKBKB
SCHEMBL14026 0.85 CCNA2 (0.35) PARP1TNK2TNK1AKT1DHODH
SCHEMBL14512 0.83 RIPK1 (0.41) HDAC4HDAC6DHODHIKBKB
SCHEMBL14232 0.79 RIPK1 (0.39) HDAC4HDAC6DHODHKDM1AIKBKB
SCHEMBL14306 0.78 CDK2 (0.38) PARP1TNK2TNK1AKT1DHODH
SCHEMBL14209 0.78 KIT (0.34) CCNT1CDK9CNR1IKBKB
SCHEMBL13804 0.77 RIPK1 (0.37) HDAC4HDAC6DHODHKDM1AIKBKB
SCHEMBL14514 0.76 RIPK1 (0.37) HDAC4HDAC6DHODHKDM1AIKBKB
SCHEMBL14311 0.76 BRD4 (0.33) BRD4BRD2BRD3CNR2
SCHEMBL14513 0.75 RIPK1 (0.46) HDAC4HDAC6METJAK2BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2488525-B1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME MELINTA THERAPEUTICS INC (US) 2018-04-25 EP disclosed
US-20160031893-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME BioVersys AG (CH) 2016-02-04 US disclosed
US-9193731-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2015-11-24 US disclosed
US-9193731-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2015-11-24 US disclosed
US-20120220566-A1 Antimicrobial Compounds and Methods of Making and Using the Same RIB-X PHARMACEUTICALS, INC. (US) 2012-08-30 US disclosed
US-20120220566-A1 Antimicrobial Compounds and Methods of Making and Using the Same RIB-X PHARMACEUTICALS, INC. (US) 2012-08-30 US disclosed
WO-2011047319-A2 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME RIB-X PHARMACEUTICALS, INC. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220566-A1 Antimicrobial Compounds and Methods of Making and Using the Same MPO, LPO, CAT HDAC4 2407/4885HDAC6 1089/4885PARP1 1324/4885
US-20160031893-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME MPO, LPO, CAT HDAC4 2407/4885HDAC6 1089/4885PARP1 1324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.